HC Wainwright Reaffirms Buy Rating for Krystal Biotech
HC Wainwright maintains its buy rating on Krystal Biotech, setting a $361 price target, a 5.12% upside from the current price.
Key Points
- On June 16, 2026, HC Wainwright reiterated its buy rating for Krystal Biotech, Inc. (KRYS) with a price target of $361.
- HC Wainwright's $361 price target implies 5.12% upside from Krystal Biotech, Inc.'s ($KRYS) current $343.43 share price.
- Krystal Biotech shares are trading around $324.75, with a market cap of $9.53 billion and a P/E ratio of 43.4.
- FMR LLC increased its holdings in Krystal Biotech by 24,359 shares, totaling 4,373,987 shares valued at approximately $1.13 billion.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright & Co. recently reiterated its buy rating on Krystal Biotech, Inc. (NasdaqGS: KRYS), setting a price target of $361. This reaffirmation came on June 16, 2026, as the company's shares traded around $324.75.
Analysts Set New Price Targets
On June 16, 2026, HC Wainwright maintained its buy rating for Krystal Biotech with a $361 price target. Citigroup also maintained a buy rating with a higher target of $378 on May 5, 2026. Evercore ISI Group, on the same day, kept its buy rating with a target of $300. Overall, the consensus among nine analysts is a strong buy, with a mean target price of $322.78.
Other Institutional Activity in Krystal Biotech
FMR LLC grew its holdings in Krystal Biotech by 24,359 shares, ending with 4,373,987 shares worth about $1.13 billion. BlackRock, Inc. added 2,639 shares, bringing its total to 3,940,456 shares valued at approximately $1.02 billion. Avoro Capital Advisors LLC held steady with 2,888,888 shares valued at about $746.26 million. Vanguard Portfolio Management LLC established a new position with 1,456,727 shares, valued at $376.3 million. Meanwhile, State Street Corp reduced its position by 27,869 shares, holding 1,314,434 shares worth around $339.54 million.
Krystal Biotech, Inc. Stock Down 2.3%
Shares of NasdaqGS:KRYS are trading near $324.75. Krystal Biotech has a market cap of about $9.53 billion, a P/E ratio of 43.4, and a forward P/E of 32.1. The stock's 52-week range spans from $127.99 to $331.49, with a 50-day moving average of $290.80 and a 200-day moving average of $242.22. The company maintains a strong financial position with a current ratio of 9.46 and a quick ratio of 8.82.
Recent Earnings
Krystal Biotech reported revenue of $417.3 million, reflecting a growth rate of 31.9%. The company's net margin stands at 53.9%, with a return on equity of 19.9%. Earnings per share (EPS) were noted at $7.45, and the next earnings report is scheduled for August 3, 2026.
Insider Buying and Selling at Krystal Biotech, Inc.
Recent planned insider sales included Krishnan Suma, President of R&D, who sold 25,000 shares on June 4, 2026, at an average price of $308.12. Krishnan Krish, President and CEO, also sold 25,000 shares on the same day at a similar price. EVP and General Counsel Thomas John Charles sold 642 shares on May 26, 2026, at $302.03, all under Rule 10b5-1 plans.
About Krystal Biotech
Krystal Biotech, Inc. is a biotechnology firm based in Pittsburgh, Pennsylvania. Founded in 2016, the company focuses on developing genetic medicines for diseases with high unmet needs. Its flagship product, VYJUVEK, is used to treat dystrophic epidermolysis bullosa, and it has several other candidates in various stages of clinical trials targeting conditions like cystic fibrosis and Hailey-Hailey disease. Led by CEO Krish S. Krishnan, the company employs about 295 people.
Bottom Line
HC Wainwright's reiterated buy rating and $361 price target underscore confidence in Krystal Biotech's growth prospects. Investors often monitor such analyst actions to gauge market sentiment, though it's important to remember that these ratings are based on past data and projections. As always, it's crucial to consider multiple factors when assessing a stock's potential.
Get Krystal Biotech, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KRYS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.